PIM2 and acute myeloid leukemia: In addition, a pharmacodynamic assessment of 4 blood samples obtained from two separate patients with AML receiving INCB053914 100 mg twice a day in the ongoing phase 1/2 trial also demonstrated an increase in PIM2 expression levels and a decrease in 4E-BP1 phosphorylation (Fig 3C).